Our differential expression analysis revealed significant upregulation of FZD2 in cancers such as bladder cancer (BLCA), breast cancer (BRCA), cholangiocarcinoma (CHOL), and STAD, while it was downregulated in kidney cancers (KICH, KIRC). Here, FZD2 is linked to kidney cancer.